WINDTREE THERAPEUTICS INC /DE/ APIC, Share-based Payment Arrangement, Increase for Cost Recognition
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $17.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-11-19
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $17.00K, a 80.23% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $32.00K, a 67.01% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $72.00K, a 56.10% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $86.00K, a 71.80% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.28M, a 58.59% decline from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.09M, a 57.36% decline from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $7.24M, a 27.34% increase from fiscal 2020.
- WINDTREE THERAPEUTICS INC /DE/ apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $5.68M, a 15.43% decline from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-09-30 | $17.00K 10-Q · filed 2025-11-19 | $49.00K derived: sum of 2 quarters · filed 2025-11-19 | $121.00K derived: sum of 3 quarters · filed 2025-11-19 | |
| 2025-06-30 | $32.00K 10-Q · filed 2025-11-19 | $104.00K derived: sum of 2 quarters · filed 2025-11-19 | ||
| 2025-03-31 | $72.00K 10-Q · filed 2025-11-19 | |||
| 2024-09-30 | $86.00K 10-Q · filed 2025-11-19 | $183.00K derived: sum of 2 quarters · filed 2025-11-19 | $347.00K derived: sum of 3 quarters · filed 2025-11-19 | |
| 2024-06-30 | $97.00K 10-Q · filed 2025-11-19 | $261.00K derived: sum of 2 quarters · filed 2025-11-19 | ||
| 2024-03-31 | $164.00K 10-Q · filed 2025-11-19 | |||
| 2023-12-31 | $1.28M 10-K · filed 2025-04-15 | |||
| 2023-09-30 | $305.00K 10-Q · filed 2024-11-26 | $687.00K derived: sum of 2 quarters · filed 2024-11-26 | $972.00K derived: sum of 3 quarters · filed 2024-11-26 | |
| 2023-06-30 | $382.00K 10-Q · filed 2024-11-26 | $667.00K derived: sum of 2 quarters · filed 2024-11-26 | ||
| 2023-03-31 | $285.00K 10-Q · filed 2024-11-26 | |||
| 2022-12-31 | $3.09M 10-K · filed 2024-04-16 | |||
| 2022-09-30 | $744.00K 10-Q · filed 2023-11-09 | $1.52M derived: sum of 2 quarters · filed 2023-11-09 | $2.29M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $781.00K 10-Q · filed 2023-11-09 | $1.55M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $770.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $7.24M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $1.63M 10-Q · filed 2022-11-14 | $3.17M derived: sum of 2 quarters · filed 2022-11-14 | $5.62M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $1.54M 10-Q · filed 2022-11-14 | $3.99M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $2.44M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $5.68M 10-K · filed 2022-03-31 | |||
| 2020-06-30 | $1.57M 10-Q · filed 2021-11-10 | $3.25M derived: sum of 2 quarters · filed 2021-11-10 | $4.77M derived: sum of 3 quarters · filed 2021-11-10 | $6.71M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-03-31 | $1.69M 10-Q · filed 2021-11-10 | $3.20M derived: sum of 2 quarters · filed 2021-11-10 | $5.14M derived: sum of 3 quarters · filed 2021-11-10 | $6.88M derived: sum of 4 quarters · filed 2021-11-10 |
| 2019-12-31 | $1.51M derived: 10-K 12 month − 3 quarters · filed 2020-04-03 | $3.45M derived: sum of 2 quarters · filed 2020-04-03 | $5.19M derived: sum of 3 quarters · filed 2020-04-03 | $6.72M 10-K · filed 2020-04-03 |
| 2019-09-30 | $1.94M 10-Q · filed 2019-11-14 | $3.68M derived: sum of 2 quarters · filed 2019-11-14 | $5.21M derived: sum of 3 quarters · filed 2019-11-14 | |
| 2019-06-30 | $1.74M 10-Q · filed 2019-11-14 | $3.27M derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2019-03-31 | $1.53M 10-Q · filed 2019-11-14 | |||
| 2018-12-31 | $1.00M 10-K · filed 2020-04-03 | |||
| 2018-09-30 | $145.00K 10-Q · filed 2019-11-14 | $285.00K derived: sum of 2 quarters · filed 2019-11-14 | $703.00K derived: sum of 3 quarters · filed 2019-11-14 | |
| 2018-06-30 | $140.00K 10-Q · filed 2019-11-14 | $558.00K derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-03-31 | $418.00K 10-Q · filed 2019-11-14 | |||
| 2017-12-31 | $1.56M 10-K/A · filed 2019-04-23 | |||
| 2016-12-31 | $1.41M 10-K · filed 2018-04-17 | |||
| 2015-12-31 | $1.70M 10-K · filed 2017-03-31 | |||
| 2014-12-31 | $2.94M 10-K · filed 2016-03-29 | |||
| 2013-12-31 | $2.21M 10-K · filed 2015-03-16 | |||
| 2012-12-31 | $2.41M 10-K · filed 2015-03-16 | |||
| 2011-12-31 | $867.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |